Malignant Uterine Neoplasm — Trials

Malignant Uterine Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,290 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 823
Recruiting: 455
Ph III recruiting: 55
Growth YoY: −4.1%
Industry share: 24%
Top sponsor: National Cancer Institute (NCI)
Termination share: 25.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (333)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06755515	A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer	enrolling by invitation	Phase 2 / Phase 3	510	Shandong New Time Pharmaceutical Co., LTDINDUSTRY	1	Jan 1, 2025	clinicaltrials

Data updated 22 days agoSource updated Jan 1, 2025source: clinicaltrials